JWJunfeng Wang

Junfeng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Junfeng Wang has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An Environmentally Sensitive Epidermal Growth Factor Receptor Probe for Turn-On Tumor Imaging and TGF-β1-Mediated Cancer Immunotherapy via the Selective Depletion of TI-Tregs

    by Yi Cao, Xingxin Wu, Guohao Wang, Hanfang Liu, Min Zeng, Xiuzhong Sun, Ning Guo, Song Huang, Weibin Zhai, Lei Jiang, et al.

    Disruptions of epidermal growth factor receptor (EGFR) are implicated in various cancers, and EGFR-overexpressing tumors are co-infiltrated with immunosuppressive tumor-infiltrating regulatory T cells (TI-Tregs) that remain difficult to target. Here, we developed a novel class of environment-sensitive EGFR probes (ES-JFTNs) by conjugating phthalimide or benzoxadiazole fluorophores to an anilinoquinazoline scaffold. The lead probe ES3-JFTN exhibits selectivity as a turn-on fluorescent agent upon EGFR binding. ES3-JFTN inhibits EGFR phosphorylation and suppresses the TGF-β1 pathway, leading to FOXP3 downregulation via the EGFR/glycogen synthase kinase 3β (GSK3β) axis and selectively depleting TI-Tregs while stimulating CD8+ T cell activation. In tumor-bearing mice, it achieves a 77.69% tumor inhibition rate, significantly outperforming gefitinib (52.40%). These findings establish ES3-JFTN as a dual-functional theranostic agent that overcomes the immunosuppressive tumor microenvironment and guides the rational design of EGFR-targeted immunotherapies.

  • A deep learning-assisted turn-on fluorescent probe for L-BPA detection with mechanistic insight

    by Yuanfeng Qi, Le Wang, Shibo Sun, Yuting Leng, Yujiao Peng, Chenqi Liu, Yongjie Lai, Samuel Han, Yuhang Zhao, Yingbo Li, et al.

  • Rational design of environment-sensitive fluorescent probes for butyrylcholinesterase and their application in biological imaging

    by Lulian Shao, Feng Wang, Yu Wang, Jiahao Du, Wenting Cao, Qingwen Zhang, Fenqin Zhao, Junfeng Wang, Wenhui Fan, Yuemin Zhou, et al.

    Butyrylcholinesterase (BChE) is closely associated with Alzheimer's disease (AD), with its expression significantly elevated in the brains of AD patients. This enzyme has emerged as a potential biomarker for monitoring AD progression. Therefore, developing a reliable chemical tool to detect BChE both in vitro and in vivo is of considerable interest. In this study, we rationally designed a series of environmentally sensitive fluorescent probes targeting BChE, based on a highly potent, selective, and reversible BChE inhibitor. Among these, the most promising probe ESP4 demonstrated an ultrafast response to BChE with exceptional sensitivity (LOD = 1.81 nM), enabling high-precision detection of BChE. Additionally, ESP4 maintained robust inhibitory activity against BChE in the low nanomolar range (IC50 = 71.78 ± 1.90 nM). Notably, ESP4 exhibited excellent selectivity for BChE, showing no interference from other biological species, including acetylcholinesterase (AChE). The probe also accurately measured the IC50 of tacrine (7.83 nM), a standard BChE inhibitor, demonstrating its reliability in evaluating BChE inhibition. Due to its high sensitivity, rapid response, and superior selectivity, ESP4 enabled real-time imaging of BChE in biological systems such as cells, zebrafish, and AD mouse models. Collectively, these findings highlighted ESP4 as a valuable tool for BChE detection, contributing to a deeper understanding of the physiological role of BChE in health and disease.


  • Rational design of an environment-sensitive fluorescent probe for monitoring butyrylcholinesterase activity and its application in Alzheimer's disease

    by Ning Guo, Feng Wang, Yu Wang, Jiahao Du, Qingwen Zhang, Wenting Cao, Jiongtao Su, Fenqin Zhao, Junfeng Wang, Xiaobin Pang, et al.

    LY36 integrates selective BChE inhibition with environment-sensitive fluorescence for real-time visualization of Alzheimer's pathology in biological models.

  • Open Access

    Editorial: Drug discovery from herbal medicines/polypeptides for neurological diseases

    by Qi Liang, Jianfeng Zhang, Li Lin, Junfeng Wang

    1.1 Alzheimer's Disease: Targeting Amyloid and Tau Pathology Two studies exemplify the potential of plant-derived compounds in combating AD (Aili et al., 2023). The first (DOI: 10.3389/fphar.2025.1500955) investigates the biosynthesis of neuroactive alkaloids, such as Huperzine A and Galantamine. Both discoveries not only deepen our understanding of plant metabolism but also offer practical pathways for the sustainable production of crucial AD treatments. Complementing this, the second study (DOI: 10.3389/fphar.2025.1497861) explores natural inhibitors of glycogen synthase kinase-3β (GSK-3β), a key enzyme driving tau hyperphosphorylation. Curcumin derivatives from Curcuma longa L. and hesperetin from Citrus × aurantium L. were shown to reduce tau pathology in transgenic mouse models, highlighting GSK-3β as a pivotal target for multi-herbal interventions.Depression, linked to impaired neuroplasticity, is addressed by two groundbreaking works (Dai et al., 2024). A review of traditional Chinese medicine (TCM) (DOI: 10.3389/fphar.2024.1426769) identifies compounds like gastrodin and saikosaponins, which upregulate BDNF expression and promote dendritic spine formation in the prefrontal cortex. Meanwhile, a meta-analysis of plant polysaccharides (DOI: 10.3389/fphar.2024.1348019) reveals their role in modulating the gut-brain axis. Polysaccharides from Astragalus and Rehmannia enhance serotonin synthesis by restoring gut microbiota diversity, offering a novel mechanism for antidepressant effects.Cerebral ischemia-reperfusion injury, a major cause of stroke disability, is tackled by studies on apigenin (DOI: 10.3389/fphar.2024.1362301) and Guipi Wan (DOI: 10.3389/fphar.2024.1346226). Apigenin, a flavonoid in Matricaria chamomilla L., was found to enhance DNA repair via PARP-1 activation, reducing infarct volume in rodent models. Guipi Wan, a TCM formulation, attenuated oxidative stress by regulating the Nrf2/HO-1 pathway, underscoring the value of multi-herbal synergies.Uncaria rhynchophylla (Miq.) Miq. (DOI: 10.3389/fphar.2024.1436481) exemplifies the therapeutic promise of alkaloids. Its rhynchophylline and isorhynchophylline demonstrated NMDA receptor antagonism, reducing glutamate excitotoxicity in Parkinson's models. Similarly, berberrubine from Berberis vulgaris L. (DOI: 10.3389/fphar.2024.1496917) protected against cisplatin-induced ototoxicity by upregulating folate biosynthesis enzymes, preserving cochlear hair cells.Innovative approaches for ocular and spinal disorders are emerging (Vargova et al., 2021). Lycium ruthenicum Murray extract (DOI: 10.3389/fphar.2024.1404119), rich in anthocyanins, preserved retinal ganglion cells in glaucoma models by inhibiting caspase-3-mediated apoptosis. For spinal cord injury, Erxian decoction metabolites (DOI: 10.3389/fphar.2024.1339956) binding PRAS40a regulator of mTOR-enhanced axonal regeneration by modulating autophagy, achieving functional recovery in rats to some extent.The efficacy of standardized herbal mixtures (Hao et al., 2023) is exemplified by a blend of Centella asiatica (L.) Urb., Echinacea purpurea (L.) Moench, and Zingiber officinale Roscoe (DOI: 10.3389/fphar.2024.1439811), which normalized cortisol levels and restored dopaminergic signaling in stress-induced depression. Xingnaojing injection (DOI: 10.3389/fphar.2024.1411026), a TCM-derived neuroprotective agent, showed a significant reduction in post-hemorrhagic stroke edema in a meta-analysis of the patients, though heterogeneity in trial design calls for stricter standardization.The Zingiber officinale Roscoe (DOI: 10.3389/fphar.2024.1372110) offers triterpenoids and polysaccharides that inhibit neuroinflammation via microglial TLR4 suppression. Its potential in treating multiple sclerosis is being explored in Phase II trials, with preliminary data showing an obvious reduction in relapse rates.Despite progress, critical hurdles remain: 1)Standardization: Batch variability in herbal extracts undermines reproducibility. This issue is expected to be resolved through the implementation of blockchain tracking with GACP, HPLC-MS fingerprint recognition, and reference standards. 2)Bioavailability: Previous studies have improved the bioavailability of natural products through nanocapsules (Amante et al., 2022), prodrug design (Beaumont et al., 2022), and synergistic formulations (Sharma et al., 2023).3)Mechanistic Complexity: Herbal polypharmacology complicates target identification. Traditionally, network pharmacology contributed to this identification. Nowadays, AI-driven docking (as used in DOI: 10.3389/fphar.2024.1339956) is playing an increasingly important role in elucidating multi-objective effects.To advance herbal medicine into the era of precision and reproducibility, future research must prioritize three interconnected domains: multi-omics integration, sustainable bioengineering, and hybrid therapeutic trials. These priorities address critical gaps in standardization, scalability, and mechanistic validation while aligning with global demands for personalized and eco-conscious healthcare solutions. 1)Omics Integration: Decoding Bioactive Signatures Herbal extracts' complexity demands metabolomics (e.g., UPLC-QTOF-MS) to map bioactive markers linked to clinical outcomes. AI-driven platforms can integrate pharmacometabolomics and gut microbiome interactions. Standardizing protocols and addressing data heterogeneity remain challenges.2)Sustainable Sourcing: CRISPR-Engineered Plants CRISPR editing resolves supply-chain instability and phytochemical variability through high-yield strains, precision chemotypes, climate resilience, and biosafety measures.3)Hybrid Trials: Herbal-Polypeptide Synergies Previous work proved that polypeptide such as BDNF-mimetic peptides was benifit for maintaining mitochondrial quality control (Ahuja et al. 2022). As such, the synergies of BDNF-mimetic peptides and natural products may be an alternatitive for neuroprotection.The...

  • A binuclear zinc complex (Zn 2 L) as ratiometric probe for the pyrophosphate (PPi) sensing

    by Mengxia Liu, Wenwen Sun, Le Wang, Zhiqiang Niu, Xiao Zhang, Dingjia Xiao, Tianjia Xiao, Junfeng Wang

    A binuclear zinc complex (Zn 2 L) was developed as a ratiometric fluorescence probe for pyrophosphate (PPi) sensing.


  • Retraction
    Open Access

    Retraction: Recent advances in total synthesis of protoberberine and chiral tetrahydroberberine alkaloids

    by Zhen-Xi Niu, Ya-Tao Wang, Jun-Feng Wang

    Retraction of ‘Recent advances in total synthesis of protoberberine and chiral tetrahydroberberine alkaloids’ by Zhen-Xi Niu et al., Nat. Prod. Rep., 2024, https://doi.org/10.1039/d4np00016a.


  • Advances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging

    by Junfeng Wang, Yingbo Li, Georges El Fakhri

    Positron emission tomography (PET) imaging employs positron-emitting radioisotopes to visualize biological processes in living subjects with high sensitivity and quantitative accuracy. As the most translational molecular imaging modality, PET can detect and image a wide range of radiotracers with minimal or no modification to parent drugs or targeting molecules. This Perspective provides a comprehensive analysis of developing PET radioligands using allosteric modulators for the metabotropic glutamate receptor subtype 4 (mGluR4) as a therapeutic target for neurological disorders. We focus on the selection of lead compounds from various chemotypes of mGluR4 positive allosteric modulators (PAMs) and discuss the challenges and systematic characterization required in developing brain-penetrant PET tracers specific for mGluR4. Through this analysis, we offer insights into the development and evaluation of PET ligands. Our review concludes that further research and development in this field hold great promise for discovering effective treatments for neurological disorders.


  • Unexpected Intermolecular C–H···O Hydrogen Bonds and 1H NMR Chemical Shifts in a Key Linker for Fluorine-18 Labeling of Dimeric Drugs

    by Zelin Wang, Bo Li, Junfeng Wang, Lu Wang

    The compound 2-{[(trifluoromethyl)sulfonyl]oxy}propane-1,3-diyl bis(4-methylbenzenesulfonate) (TPB) is a crucial intermediate in the synthesis of F-18-radiolabeled cromolyn derivatives. In this work, we combine H-1 NMR spectroscopy, X-ray crystallography, ab initio molecular dynamics, and NMR calculations to examine the structure, interactions, and solvation dynamics of the TPB molecule. In CDCl3, the CH2 groups within its glyceryl-derived linker exhibit a single set of proton signals in the H-1 NMR measurements. However, when TPB is dissolved in DMSO-d(6), distinct splitting patterns emerge despite its seemingly symmetric chemical structure. Crystallographic analysis further unveils the absence of overall symmetry in its three-dimensional arrangement. To elucidate these unique NMR features, we carry out ab initio molecular dynamics simulations and characterize the solvation structures and dynamics of TPB in CHCl3 and DMSO solutions. In contrast to the predominantly nonpolar nature of the CHCl3 solvents, DMSO directly participates in C-HO hydrogen-bonding interactions with the solute molecule, leading to the splitting of its -CH2 chemical shifts into two distinct distributions. The comprehensive understanding of the structure and solvation interactions of TPB provides essential insights into its application in the radiofluorination reactions of cromolyn derivatives and holds promise for the future development of radiolabeled dimeric drugs.